GLP-1 and GIP differ remarkably in their glucoregulatory actions in healthy rats when DPP-4 is inhibited. These previously unrecognized actions of DPP-4 inhibitors could have implications for future use in humans.FreyseInstitute of Diabetes 'Gerhardt Katsch' KarlsburgErnst-Joachim...
diabetes:a randomized,double-blind,placebo-controlled trial 2011(05) 22.Nauck M;Stockmann F;Ebert R Reduced incretin effect in type 2 (noninsulin-dependent) diabetes[外文期刊] 1986(01) 23.Rosenstock J;Kim SW;Baron MA Efficacy and tolerability of initial combination therapy with vildagliptin and ...
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in...
Indirect comparison of the two pharmacological approaches reported in meta-analyses of RCTs of DPP-4 inhibitors, on the one hand, and GLP-1 receptor agonists, on the other hand, confirmed such clinical differences between the two incretin-based approaches [14]. Meta-regression of RCTs of the...
controlled clinical pilot trials on DPP-4 inhibitors for autoimmune diabetes [96,97,98,99,100,101] (Table2). Incretin-based therapy in T1DM patients improved glycemic control and reduced both hypoglycemia incidence and insulin requirements. However, there are discrepancies among these trials regarding...
5. Annayya R. Aroor,James R. Sowers,Guanghong Jia,et al.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.Am J Physiol Heart Circ Physiol,2014,307: H477–H492. 6. Sang Ah Lee, Young Ree Kim, Eun Jin Yang...
Rationale: DPP-4 (dipeptidyl peptidase-4) inhibitors have increased the risk of heart failure events in both randomized clinical trials and observational s... Packer,Milton - 《Circulation Research》 被引量: 6发表: 2018年 DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during...
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in...
Incretin therapies - highlighting common features and differences in the modes of action of GLP-1 receptor agonists and DPP-4 inhibitors DPP-4 inhibitorincretin enhancerincretin mimeticstype 2 diabetes mellitusmode of actionOver the last few years, the incretin-based therapies have emerged as ... ...
Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The first available DPP-4 inhibitors are sitagliptin and vildagliptin. These compounds are orally active and have been shown to ...